MoneyWorks4Me

Bacil Pharma - Quaterly Results

16 May 2023 Evaluate
Revenue reduced marginally to stand at Rs. 0.00 millions during the quarter ended March 2023. The figure stood at Rs. 0.00 millions during the year-ago period.The Net Loss for the quarter ended March 2023 is Rs. -0.76 millions as compared to Net Loss of Rs. -37.37 millions of corresponding quarter ended March 2022 Operating profit Margin for the quarter ended March 2023 improved to -0.75% as compared to -37.36% of corresponding quarter ended March 2022


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202303 202203 % Var 202303 202203 % Var 202303 202203 % Var
Sales 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other Income 0.09 0.08 12.50 1.15 0.58 98.28 1.15 0.58 98.28
PBIDT -0.75 -37.36 -97.99 -0.99 -38.56 -97.43 -0.99 -38.56 -97.43
Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PBDT -0.75 -37.36 -97.99 -0.99 -38.56 -97.43 -0.99 -38.56 -97.43
Depreciation 0.01 0.01 0.00 0.03 0.04 -25.00 0.03 0.04 -25.00
PBT -0.76 -37.37 -97.97 -1.02 -38.60 -97.36 -1.02 -38.60 -97.36
TAX 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT -0.76 -37.37 -97.97 -1.02 -38.60 -97.36 -1.02 -38.60 -97.36
Equity 58.90 58.90 0.00 58.90 58.90 0.00 58.90 58.90 0.00
PBIDTM(%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Peers
Company Name CMP
Sun Pharma. Inds. 1820.00
Dr. Reddys Labs. 1236.00
Cipla 1350.00
Lupin 2042.00
Zydus Lifesciences 1163.35
View more..